Scarica l'app Stockscreener
1.65
1.79%
-0.03
Dopo l'orario di chiusura:
1.63
-0.02
-1.21%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMEA Giù?
Forum
Previsione
Biomea Fusion Inc Borsa (BMEA) Ultime notizie
Real time pattern detection on Biomea Fusion Inc. stockWeekly Trade Analysis & Free Risk Controlled Daily Trade Plans - newser.com
Is Biomea Fusion Inc. meeting your algorithmic filter criteriaJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
Biomea Fusion Inc. stock retracement – recovery analysisWeekly Trading Summary & Safe Entry Momentum Stock Tips - newser.com
Should you wait for a breakout in Biomea Fusion Inc.Portfolio Value Summary & Fast Exit and Entry Strategy Plans - newser.com
Biomea Fusion (NASDAQ:BMEA) Trading Up 6.5%What's Next? - MarketBeat
Tools to assess Biomea Fusion Inc.’s risk profileMarket Sentiment Review & Technical Entry and Exit Alerts - newser.com
Biomea Fusion (NASDAQ:BMEA) Given "Sell (E+)" Rating at Weiss Ratings - MarketBeat
Does Biomea Fusion Inc. fit your quant trading model2025 Market Overview & Precise Swing Trade Entry Alerts - newser.com
What analysts say about Biomea Fusion Inc stockBollinger Bands Signals & Free Unmatched Market Gains - earlytimes.in
Why Biomea Fusion (BMEA) Is Up After Positive Diabetes Data and $25M Equity Raise – And What’s Next - Yahoo Finance
Biomea Fusion Announces Positive Phase II Study Results - MSN
Why Biomea Fusion (BMEA) Is Up on Promising Phase II Diabetes Data and What It Could Mean Next - simplywall.st
Nasdaq Tumbles 200 Points; Trilogy Metals Shares Spike Higher - Benzinga
Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups - insights.citeline.com
Biomea’s ‘durable’ menin inhibitor advancing in hard-to-treat diabetes - BioWorld MedTech
Biomea Fusion: Surging On Data, Sinking On FundingI'm On The Sidelines - Seeking Alpha
Traders Purchase High Volume of Biomea Fusion Call Options (NASDAQ:BMEA) - MarketBeat
Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study - inkl
Dow Jumps Over 100 Points; McCormick Earnings Top Views - Benzinga
Biomea Fusion announces pricing of public offering of securities - MSN
Biomea Fusion prices $25 million public offering of shares and warrants - Investing.com
Biomea Fusion plunges on $25 mln stock-and-warrants offering - TradingView
Biomea Fusion Announces Pricing of Public Offering of Securities - The Manila Times
D. Boral Capital Maintains Biomea Fusion (BMEA) Buy Recommendation - Nasdaq
$25M Offering: Biomea Fusion Prices 11.2M Shares & Warrants at $2.05 — Closing Oct 8, 2025 - Stock Titan
Biomea Fusion announces proposed public offering of securities - MarketScreener
Biomea Fusion, Inc. (BMEA) Stock: Volatile Surge Ahead of Jefferies-Led Equity Offering - parameter.io
Biomea's diabetes drug shows promise, may work for those not responding to GLP-1 - MarketScreener
Biomea announces positive 52-week results from phase II COVALENT-111 study in type 2 diabetes - MarketScreener
Biomea Fusion Reports Phase 2 Data in Diabetes, Launches Stock Offering - MarketScreener
Biomea Fusion Announces Proposed Public Offering of Securities - GlobeNewswire
Biomea Fusion launches public offering of common stock and warrants - Investing.com
Biomea Fusion launches public offering of common stock and warrants By Investing.com - Investing.com Australia
Biomea Fusion reports 52-week results from Phase II diabetes trial - Investing.com
Biomea Fusion Reports Positive 52-Week Results from Phase II COVALENT-111 Study of Icovamenib in Type 2 Diabetes Patients - Quiver Quantitative
1.8% HbA1c reduction sustained at Week 52 — Biomea Fusion's icovamenib shows durable benefit - Stock Titan
Why Biomea Fusion Inc. stock remains undervaluedTrade Risk Summary & Safe Entry Zone Identification - newser.com
Visualizing Biomea Fusion Inc. stock with heatmapsVolume Spike & Weekly High Potential Alerts - newser.com
Biomea Fusion (NASDAQ:BMEA) Receives “Buy” Rating from D. Boral Capital - Defense World
BMEA: D. Boral Capital Maintains Buy Rating with $16 PT | BMEA S - GuruFocus
Biomea Fusion's (BMEA) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
How geopolitical tensions affect Biomea Fusion Inc. stockShort Setup & Smart Money Movement Alerts - newser.com
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Biomea Fusion, Inc. reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
48,000 Stock Options: Biomea Fusion Makes Key Inducement Grant Under 2023 Equity Plan - Stock Titan
What drives Biomea Fusion Inc stock priceExit Strategy Tips & Affordable Growth Investments - earlytimes.in
Biomea Fusion appoints Mick Hitchcock to succeed Thomas Butler as interim CEO - MSN
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):